Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801815 | 0.84 | ESR2 (0.41) | ESR1ESR2MAOAMAOB | |
| SCHEMBL6795653 | 0.84 | CES2 (0.38) | ESR1ESR2MAOAMAOBCES2 | |
| SCHEMBL6806691 | 0.81 | ESR2 (0.46) | ESR1ESR2MAOAMAOBPRKCI | |
| SCHEMBL6796909 | 0.80 | ESR2 (0.43) | ESR1ESR2CSNK2A1MAOAMAOB | |
| SCHEMBL6794708 | 0.78 | PBRM1 (0.46) | ESR1ESR2MAOAMAOBPRKCI | |
| SCHEMBL6796255 | 0.74 | ESR2 (0.35) | ESR1ESR2CSNK2A1CA1CA2 | |
| SCHEMBL6794474 | 0.73 | ESR2 (0.45) | ESR1ESR2MAOAMAOBPRKCI | |
| SCHEMBL6806169 | 0.73 | MAOA (0.46) | ESR1ESR2MAOAMAOBPRKCI | |
| SCHEMBL6800106 | 0.70 | MAOA (0.47) | ESR1ESR2MAOAMAOBCA1 | |
| SCHEMBL6794055 | 0.70 | ESR1 (0.44) | ESR1ESR2MAOAMAOBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | ESR1 19/4885ESR2 5/4885CSNK2A1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.